MedDataX Logo

Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease

NCT ID: NCT00573469

Last Updated: 2012-07-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether treatment with D9421-C for 8 weeks in Japanese patients with mild to moderate active Crohn's disease will improve their symptoms of Crohn's disease and quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

NCT01514240

Crohn's Disease
COMPLETED PHASE3

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

NCT03599622

Granulomatous Colitis Crohn's Disease Crohn's Enteritis +1 more
TERMINATED PHASE2

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01203631

Inflammation Crohn's Disease
COMPLETED PHASE2

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

NCT00584740

Crohn's Disease
TERMINATED PHASE2

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946

Crohn's Disease
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

D9421-C 9 mg

Group Type ACTIVE_COMPARATOR

D9421-C, 9mg

Intervention Type DRUG

D9421-C 9 mg was given once daily for 8 weeks.

2

D9421-C 15 mg

Group Type ACTIVE_COMPARATOR

D9421-C, 15mg

Intervention Type DRUG

D9421-C 15 mg was given once daily for 8 weeks.

3

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

D9421-C matching placebo was given once daily for 8 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D9421-C, 9mg

D9421-C 9 mg was given once daily for 8 weeks.

Intervention Type DRUG

D9421-C, 15mg

D9421-C 15 mg was given once daily for 8 weeks.

Intervention Type DRUG

Placebo

D9421-C matching placebo was given once daily for 8 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female or male aged ≥ 18 and ≤ 65 years
* Diagnosis of Crohn's Disease

Exclusion Criteria

* Having ileostomy or pouch and/or colostomy
* Having previous gastric surgery
* Having a known or suspected systemic infection
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Masataka Date, MD, PhD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Nagoya, Aichi-ken, Japan

Site Status

Research Site

Sakura, Chiba, Japan

Site Status

Research Site

Chikushino-shi, Fukuoka, Japan

Site Status

Research Site

Fukuoka, Fukuoka, Japan

Site Status

Research Site

Kurume, Fukuoka, Japan

Site Status

Research Site

Hashima-gun, Gifu, Japan

Site Status

Research Site

Fukuyama, Hiroshima, Japan

Site Status

Research Site

Hiroshima, Hiroshima, Japan

Site Status

Research Site

Asahikawa, Hokkaido, Japan

Site Status

Research Site

Sapporo, Hokkaido, Japan

Site Status

Research Site

Kobe, Hyōgo, Japan

Site Status

Research Site

Kyoto, Kyoto, Japan

Site Status

Research Site

Ōita, Oita Prefecture, Japan

Site Status

Research Site

Kurashiki, Okayama-ken, Japan

Site Status

Research Site

Osaka, Osaka, Japan

Site Status

Research Site

Suita, Osaka, Japan

Site Status

Research Site

Tokorozawa, Saitama, Japan

Site Status

Research Site

Shinjuku-ku, Tokyo, Japan

Site Status

Research Site

Toyama, Toyama, Japan

Site Status

Research Site

Itami, , Japan

Site Status

Research Site

Nishinomiya, , Japan

Site Status

Research Site

Tokyo, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

References

Explore related publications, articles, or registry entries linked to this study.

Suzuki Y, Motoya S, Takazoe M, Kosaka T, Date M, Nii M, Hibi T. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis. 2013 Apr;7(3):239-47. doi: 10.1016/j.crohns.2012.06.006. Epub 2012 Jul 4.

Reference Type DERIVED
PMID: 22766525 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D9421C00002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
NCT01277666 COMPLETED PHASE3
Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine
NCT00946946 COMPLETED PHASE3
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
NCT04102111 TERMINATED PHASE2
Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease
NCT00792740 TERMINATED PHASE1/PHASE2
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
NCT02877134 COMPLETED PHASE2
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
NCT04151225 WITHDRAWN PHASE2
MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients
NCT01959165 COMPLETED PHASE2
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
NCT02048618 COMPLETED PHASE2
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
NCT01536418 TERMINATED PHASE3
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
NCT01751152 COMPLETED PHASE2
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097 TERMINATED PHASE3
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
NCT04877990 COMPLETED PHASE2
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
NCT00102921 COMPLETED PHASE2
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
NCT01276509 COMPLETED PHASE2
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
NCT03992469 ACTIVE_NOT_RECRUITING PHASE1
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
NCT01466374 COMPLETED PHASE2
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
NCT02378688 COMPLETED PHASE2
A Pilot Study of FFP104 in Subjects With Crohn's Disease
NCT02465944 UNKNOWN PHASE1/PHASE2
A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
NCT02039063 COMPLETED PHASE1/PHASE2
Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT00655733 COMPLETED PHASE2
A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease
NCT03677648 COMPLETED PHASE2
A Study of Abatacept in Patients With Active Crohn's Disease
NCT00406653 TERMINATED PHASE3
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095 ACTIVE_NOT_RECRUITING PHASE3
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
NCT00306215 COMPLETED PHASE2
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
NCT05470985 TERMINATED PHASE2/PHASE3